Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study
Fluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MI...
Main Authors: | , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-10-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332221008362 |
id |
doaj-d54980683e2340cfbd3b76108f868123 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Florian Lemaitre Fabien Fily Jean-Baptiste Foulquier Matthieu Revest Vincent Jullien Antoine Petitcollin Pierre Tattevin Camille Tron Jean-Louis Polard Marie-Clémence Verdier Emmanuelle Comets Denis Huten Cédric Arvieux Eric Bellissant Bruno Laviolle |
spellingShingle |
Florian Lemaitre Fabien Fily Jean-Baptiste Foulquier Matthieu Revest Vincent Jullien Antoine Petitcollin Pierre Tattevin Camille Tron Jean-Louis Polard Marie-Clémence Verdier Emmanuelle Comets Denis Huten Cédric Arvieux Eric Bellissant Bruno Laviolle Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study Biomedicine & Pharmacotherapy Ofloxacin Pharmacokinetics Bone infection Joint infection Modeling |
author_facet |
Florian Lemaitre Fabien Fily Jean-Baptiste Foulquier Matthieu Revest Vincent Jullien Antoine Petitcollin Pierre Tattevin Camille Tron Jean-Louis Polard Marie-Clémence Verdier Emmanuelle Comets Denis Huten Cédric Arvieux Eric Bellissant Bruno Laviolle |
author_sort |
Florian Lemaitre |
title |
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study |
title_short |
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study |
title_full |
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study |
title_fullStr |
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study |
title_full_unstemmed |
Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop study |
title_sort |
development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: the fluo-pop study |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2021-10-01 |
description |
Fluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MIC ratio above 115 h maximizes drug efficacy. However, data on OAI patients are lacking and a simple approach to access AUCs is still a clinical issue. We conducted a prospective, single-center study in 30 OAI patients hospitalized in the Rennes University Hospital to model ofloxacin pharmacokinetics and to define a limited sampling strategy (LSS) suitable for ofloxacin and levofloxacin treatments. Modeling was conducted with the Monolix software. The final model was externally validated using levofloxacin data. Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens. Two hundred and ninety-seven (297) ofloxacin concentrations were available for the pharmacokinetic modeling. Ofloxacin pharmacokinetics was best described using a bicompartmental model with a first order elimination, and a transit compartment model absorption. CKD-EPI and sex explained half of ofloxacin pharmacokinetic variability. For LSS, the 0, 1 h and 3 h sampling scheme resulted in the best approach both for BID and TID dosages (R2 adjusted = 91.1% and 95.0%, outliers = 4.8% and 5.0%, respectively). PTA allows choosing the best drug and dosage according to various hypotheses. A simple 3-sample protocol (pre-dose, 1 h after intake and 3 h after intake) to estimate ofloxacin and levofloxacin AUC allows optimal drug dosage for the treatment of osteoarticular infections. |
topic |
Ofloxacin Pharmacokinetics Bone infection Joint infection Modeling |
url |
http://www.sciencedirect.com/science/article/pii/S0753332221008362 |
work_keys_str_mv |
AT florianlemaitre developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT fabienfily developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT jeanbaptistefoulquier developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT matthieurevest developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT vincentjullien developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT antoinepetitcollin developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT pierretattevin developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT camilletron developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT jeanlouispolard developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT marieclemenceverdier developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT emmanuellecomets developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT denishuten developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT cedricarvieux developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT ericbellissant developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy AT brunolaviolle developmentofadosingadjustmenttoolforfluoroquinolonesinosteoarticularinfectionsthefluopopstudy |
_version_ |
1717376423962869760 |
spelling |
doaj-d54980683e2340cfbd3b76108f8681232021-09-19T04:54:33ZengElsevierBiomedicine & Pharmacotherapy0753-33222021-10-01142112053Development of a dosing-adjustment tool for fluoroquinolones in osteoarticular infections: The Fluo-pop studyFlorian Lemaitre0Fabien Fily1Jean-Baptiste Foulquier2Matthieu Revest3Vincent Jullien4Antoine Petitcollin5Pierre Tattevin6Camille Tron7Jean-Louis Polard8Marie-Clémence Verdier9Emmanuelle Comets10Denis Huten11Cédric Arvieux12Eric Bellissant13Bruno Laviolle14Univ Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, France; Correspondence to: Department of Pharmacology, Rennes University Hospital, 2, rue Henri Le Guilloux CEDEX, 35033 Rennes, France.Epicentre, 55 rue Crozatier, 75012, Paris, France; Infectious Diseases Unit, Broussais Hospital, Saint Malo, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceINSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, France; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, FranceUniversity Paris 13, groupe hospitalier Paris Seine-Saint-Denis, Assistance publique-Hôpitaux de Paris, 93000 Bobigny, France; Molecular Mycology Unit-CNRS UMR 2000, Pasteur Institute, 75015 Paris, FranceINSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceINSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, France; Infectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceDepartment of Orthopaedic Surgery and Traumatology, Pontchaillou University Hospital, 2 Avenue Henri Le Guilloux, 35203 Rennes, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceDepartment of Orthopaedic Surgery and Traumatology, Pontchaillou University Hospital, 2 Avenue Henri Le Guilloux, 35203 Rennes, FranceInfectious Diseases and Intensive Care Unit, Pontchaillou University Hospital, Rennes, France; University of Rennes, Inserm, BRM (Bacterial Regulatory RNAs and Medicine), UMR, France; Great West Reference centers for Complex Bone and Joint Infections (CRIOGO), FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceUniv Rennes, CHU Rennes, Inserm, EHESP, Irset (Institut de recherche en santé, environnement et travail) - UMR_S 1085, F-35000 Rennes, France; INSERM, Centre d’Investigation Clinique, CIC 1414, F-35000 Rennes, FranceFluoroquinolones efficacy depend on both the drug exposure and the level of drug resistance of the bacteria responsible for the infection. Specifically for the Staphylococcus species, which is the microorganism mainly involved in osteoarticular infections (OAI), in-vitro data reported that an AUC/MIC ratio above 115 h maximizes drug efficacy. However, data on OAI patients are lacking and a simple approach to access AUCs is still a clinical issue. We conducted a prospective, single-center study in 30 OAI patients hospitalized in the Rennes University Hospital to model ofloxacin pharmacokinetics and to define a limited sampling strategy (LSS) suitable for ofloxacin and levofloxacin treatments. Modeling was conducted with the Monolix software. The final model was externally validated using levofloxacin data. Monte-Carlo simulations were used to evaluate the probability of target attainment (PTA) of different dosing regimens. Two hundred and ninety-seven (297) ofloxacin concentrations were available for the pharmacokinetic modeling. Ofloxacin pharmacokinetics was best described using a bicompartmental model with a first order elimination, and a transit compartment model absorption. CKD-EPI and sex explained half of ofloxacin pharmacokinetic variability. For LSS, the 0, 1 h and 3 h sampling scheme resulted in the best approach both for BID and TID dosages (R2 adjusted = 91.1% and 95.0%, outliers = 4.8% and 5.0%, respectively). PTA allows choosing the best drug and dosage according to various hypotheses. A simple 3-sample protocol (pre-dose, 1 h after intake and 3 h after intake) to estimate ofloxacin and levofloxacin AUC allows optimal drug dosage for the treatment of osteoarticular infections.http://www.sciencedirect.com/science/article/pii/S0753332221008362OfloxacinPharmacokineticsBone infectionJoint infectionModeling |